Alzamend Neuro lithium trial data accepted for Barcelona MRI workshop

August 18, 2026 8:01 AM

Alzamend Neuro, Inc. (NASDAQ: ALZN) announced that pharmacokinetic imaging data from its Phase 1/2A clinical trial of AL001, an organic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found